Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Free Cash Flow (2017 - 2020)

Monopar Therapeutics (MNPR) has disclosed Free Cash Flow for 4 consecutive years, with -$1.2 million as the latest value for Q4 2020.

  • Quarterly Free Cash Flow fell 85.54% to -$1.2 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was -$4.7 million through Dec 2020, down 54.5% year-over-year, with the annual reading at -$12.2 million for FY2025, 90.52% down from the prior year.
  • Free Cash Flow hit -$1.2 million in Q4 2020 for Monopar Therapeutics, up from -$1.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$305128.0 in Q2 2017 to a low of -$1.3 million in Q3 2020.
  • Historically, Free Cash Flow has averaged -$811744.3 across 4 years, with a median of -$780856.0 in 2018.
  • Biggest YoY gain for Free Cash Flow was 49.82% in 2018; the steepest drop was 159.67% in 2018.
  • Year by year, Free Cash Flow stood at -$816021.0 in 2017, then soared by 36.37% to -$519212.0 in 2018, then fell by 28.79% to -$668705.0 in 2019, then plummeted by 85.54% to -$1.2 million in 2020.
  • Business Quant data shows Free Cash Flow for MNPR at -$1.2 million in Q4 2020, -$1.3 million in Q3 2020, and -$995474.0 in Q2 2020.